Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023

2 years ago

Additional biomarker data up to two years of treatment continue to demonstrate rapid and sustained normalization of CSF heparan sulfate…

Aziyo Biologics Announces Publication of a CanGaroo® Case Study Demonstrating Bioenvelope Benefits for Reoperative Procedures

2 years ago

Case provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable…

Orion Corporation: Managers’ transactions – Hilpi Rautelin

2 years ago

ORION CORPORATION MANAGERS’ TRANSACTIONS 30 AUGUST 2023 at 15.30 EEST                       Orion Corporation: Managers’ transactions – Hilpi Rautelin Orion Corporation has…

Clene to Present at Upcoming September Conferences

2 years ago

SALT LAKE CITY, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its…

Todos Announces Notice of Allowance From USPTO for Patent Application Covering Use of Compositions In Tollovid™ and Tollovir™ Ingredients

2 years ago

Claims covering inhibition of 3CL protease, inflammation and autophagy underscore Dr. Dorit Arad’s lifelong work NEW YORK, NY, ALPHARETTA, GA…

Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

2 years ago

HOUSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation…

Cognition Therapeutics Announces Participation in Upcoming September Conferences

2 years ago

PURCHASE, N.Y., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative…

Compass Therapeutics to Participate in Upcoming Investor Events

2 years ago

BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based…

BioHarvest Sciences Reports Q2 2023 Results Demonstrating Continued Growth Momentum

2 years ago

Q2 VINIA® revenues of USD 2.75M represent growth of 228% compared to Q2 2022 and 27% compared to Q1 2023…

LevelJump Healthcare Corp. Announces Sale of Real Time Medical Investment

2 years ago

Toronto, Ontario--(Newsfile Corp. - August 30, 2023) - LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("LevelJump" or the…